Ireland’s life sciences sector continues to expand in 2025, but in a more measured and strategic way. While capital projects are progressing across the country, companies are taking a cautious approach to resourcing, onboarding, and long-term workforce planning. The result is an industry balancing its strong growth ambitions with operational discipline amid global uncertainty.
Growth Across Ireland but More Selective
Major investments are underway in Cork, Limerick, Kerry, and Dublin, reinforcing Ireland’s global reputation as a life sciences hub. However, resourcing and onboarding are progressing at a steadier, more selective pace. Resourcing decisions are taking longer to finalise, reflecting a shift towards careful planning rather than rapid expansion.
The Double Challenge: Specialist Talent & Sustainability
Two critical challenges stand out in 2025:
-
Specialist talent scarcity – Skills in MES, Delta V, Bioprocessing, Tech Transfer, Validation, and Sterile Manufacturing remain in short supply.
-
Sustainability demands – With CSRD rules coming into force, companies are expanding expertise in compliance, emissions reporting, and energy efficiency.
To bridge the gaps, organisations are increasingly relying on contract specialists, targeted upskilling, and international recruitment.
Projects Driving Momentum
Despite the cautious outlook, significant capital projects are fuelling expansion:
-
Eli Lilly, Limerick – €927m
-
Novo Nordisk, Athlone – €85m
-
BMS, Dublin – €132m
-
Astellas, Kerry – €330m
This wave of investment is also supporting a trend towards regionalisation. Emerging hubs in Limerick, Athlone, Shannon, and Kerry are reducing pressure on Dublin and Cork, while giving professionals more opportunities to work closer to home.
Workforce Shifts: Tech to Pharma
The workforce landscape is evolving:
-
From Tech to Pharma – Layoffs in major tech firms such as Intel are pushing engineers, data specialists, and project managers into life sciences, strengthening digital and automation capabilities.
-
Pharma Restructuring – At the same time, companies like Novo Nordisk are streamlining, with plans for 9,000 global job cuts despite record revenues.
-
Big Questions Ahead – Will top-tier talent fuel new ventures? Is consolidation inevitable? And how will leaders strike a balance between growth and discipline?
Current Challenges for 2025
Looking ahead, life sciences leaders in Ireland must navigate:
-
Specialist talent gaps – Ongoing shortages in digital, data, and biologics expertise.
-
Cost vs compliance – Rising inflation pressures collide with stricter regulations.
-
Retention hurdles – Skilled professionals demand flexibility, purpose, and clarity — not just pay.
-
Extended timelines – Supply chain disruption, tariffs, and slower decision-making are delaying project delivery.
Why the West of Ireland Matters Too
As the life sciences sector expands regionally, we’re seeing increasing relevance of areas outside the traditional hubs. For more on how global companies are viewing investment opportunities in the west, check out Why the West of Ireland Means Business for Global Companies. This article illustrates how geography, infrastructure, local talent pools, and regional policy supports are making the west an increasingly attractive option.
Final Thoughts
The second half of 2025 will test the resilience of Ireland’s life sciences industry. While investment remains strong, companies are taking a disciplined approach to growth, carefully balancing opportunity with operational realities. For professionals, this means new opportunities across regions and disciplines but also a market that demands adaptability, specialist skills, and a commitment to long-term sustainability.